Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EW 
Edwards Lifesciences Corp (EW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: EW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $87.73
1 Year Target Price $87.73
| 10 | Strong Buy |
| 4 | Buy |
| 17 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.24% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 45.54B USD | Price to earnings Ratio 32.46 | 1Y Target Price 87.73 |
Price to earnings Ratio 32.46 | 1Y Target Price 87.73 | ||
Volume (30-day avg) 32 | Beta 1.07 | 52 Weeks Range 64.01 - 83.00 | Updated Date 09/14/2025 |
52 Weeks Range 64.01 - 83.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 72.96% | Operating Margin (TTM) 28.12% |
Management Effectiveness
Return on Assets (TTM) 8.42% | Return on Equity (TTM) 15.53% |
Valuation
Trailing PE 32.46 | Forward PE 28.17 | Enterprise Value 42181747000 | Price to Sales(TTM) 8.01 |
Enterprise Value 42181747000 | Price to Sales(TTM) 8.01 | ||
Enterprise Value to Revenue 7.42 | Enterprise Value to EBITDA 23.08 | Shares Outstanding 587100032 | Shares Floating 581105709 |
Shares Outstanding 587100032 | Shares Floating 581105709 | ||
Percent Insiders 0.91 | Percent Institutions 88.34 |
Upturn AI SWOT
Edwards Lifesciences Corp
Company Overview
History and Background
Edwards Lifesciences was founded in 1958 by Miles 'Lowell' Edwards and Albert Starr, pioneering the first commercially available artificial heart valve. Initially part of American Hospital Supply Corporation (later Baxter International), it became an independent public company in 2000, focusing on heart valve technologies and hemodynamic monitoring.
Core Business Areas
- Transcatheter Aortic Valve Replacement (TAVR): This segment focuses on minimally invasive heart valve replacement procedures, replacing diseased aortic valves without open-heart surgery. Key products include the SAPIEN family of valves.
- Surgical Structural Heart: This segment develops and manufactures surgical heart valves, including tissue and mechanical valves, and related technologies used in open-heart surgery.
- Critical Care: This segment provides hemodynamic monitoring systems used in intensive care units and surgical settings to optimize patient care.
Leadership and Structure
The current CEO is Bernard J. Zovighian. The organizational structure is typical of a large medical device company, with functional departments such as R&D, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- SAPIEN 3 Transcatheter Heart Valve: Edwards' SAPIEN 3 valve is a leading TAVR system globally. Competitors include Medtronic's Evolut and Abbott's Portico. It is estimated to hold a significant portion of the TAVR market. Estimated TAVR market share for Edwards Lifesciences is around 50% in the US and Globally. Market size for 2024 estimated at $6 Billion USD with Edwards leading.
- INSPIRIS RESILIA Aortic Valve: A surgical aortic valve designed for durability and ease of implantation. Competitors include Medtronic and Abbott in the surgical valve market. It has a leading role in surgical aortic valves. Revenue associated with INSPIRIS RESILIA is significant within Edwardsu2019 surgical structural heart sales.
- HemoSphere Advanced Monitoring Platform: Advanced hemodynamic monitoring system for critical care. Competitors include ICU Medical and Philips. The HemoSphere platform enhances real-time data and AI guided tools. Annual revenue is around $300 million USD.
Market Dynamics
Industry Overview
The medical device industry, particularly cardiovascular, is characterized by innovation, regulation, and aging populations driving demand. Growth is fueled by technological advancements, minimally invasive procedures, and expanded indications for existing therapies.
Positioning
Edwards Lifesciences holds a leadership position in heart valve technologies, particularly in TAVR. Its competitive advantages include strong brand reputation, extensive clinical data, and a robust R&D pipeline.
Total Addressable Market (TAM)
The global heart valve market is estimated to be around $10 billion and growing. Edwards Lifesciences is positioned well to capture a significant share of this market, given its leadership in TAVR and surgical heart valves. The Transcatheter Mitral and Tricuspid Therapies (TMTT) is also expanding. It's estimated to be around $3 Billion USD.
Upturn SWOT Analysis
Strengths
- Market leadership in TAVR
- Strong brand reputation
- Extensive clinical data supporting products
- Robust R&D pipeline
- Global presence
Weaknesses
- High reliance on TAVR segment
- Vulnerability to reimbursement changes
- Exposure to product liability litigation
- Competition in emerging markets
Opportunities
- Expanding TAVR indications to younger patients
- Developing next-generation heart valve technologies
- Growth in emerging markets
- Expanding into adjacent therapeutic areas (e.g., mitral and tricuspid valve therapies)
Threats
- Increased competition in TAVR market
- Reimbursement pressures from healthcare providers
- Technological obsolescence
- Economic downturns affecting hospital budgets
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Edwards Lifesciences maintains a competitive advantage through its leading TAVR technology, strong brand reputation, and extensive clinical data. However, it faces increasing competition from Medtronic, Abbott, and Boston Scientific in various segments.
Major Acquisitions
Harpoon Medical
- Year: 2017
- Acquisition Price (USD millions): 250
- Strategic Rationale: Harpoon Medical had an innovative beating-heart, minimally invasive surgical solution for mitral valve repair, enhancing Edwards' portfolio.
Growth Trajectory and Initiatives
Historical Growth: Edwards Lifesciences has experienced strong growth in recent years, driven by its leading position in the TAVR market and expanding global presence.
Future Projections: Analysts project continued growth for Edwards Lifesciences, driven by increasing adoption of TAVR, expansion into new markets, and development of next-generation technologies. Low single digit growth rates.
Recent Initiatives: Recent strategic initiatives include expanding TAVR indications, investing in R&D for mitral and tricuspid valve therapies, and expanding its presence in emerging markets.
Summary
Edwards Lifesciences is a strong company, leading the TAVR market with innovative technologies and a solid brand. It's benefiting from aging populations driving demand for its heart valve solutions. However, Edwards Lifesciences should be aware of increasing competition and reimbursement pressures which could affect future financial performance and growth. Strategic initiatives in mitral and tricuspid therapies are critical.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports (e.g., from major investment banks)
- Industry News and Publications
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Investment decisions should be based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edwards Lifesciences Corp
Exchange NYSE | Headquaters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15800 | Website https://www.edwards.com |
Full time employees 15800 | Website https://www.edwards.com | ||
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.